Pengaruh Lama Penggunaan Kombinasi ARV (TDF+3TC+EFV) terhadap Jumlah Sel CD4+ Pasien HIV/AIDS

Yunita, Ema Pristi; Winarsih, Sri; Deasury, Nisa R.

doi:10.15416/ijcp.2020.9.3.219

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hasil summary effect menunjukkan bahwa terapi ARV memberikan perubahan jumlah CD4 dalam tubuh sesuai pada penelitian Wardhani (2019), Febriani (2019), Romadhoni (2018), Yunita (2020), Widiyanti (2018) yang juga menunjukkan bahwa pasien dengan HIV/AIDS yang melakukan terapi ARV mengalami perubahan jumlah CD4 yang ada di dalam tubuh (15)(16)(17)(18)(19).…”

Section: Metodeunclassified

Meta Analisis Beda Rata-Rata Pada Pengobatan HIV/AIDS Di Indonesia

Saniputra

2022

preventif

View full text Add to dashboard Cite

Terapi ARV masih menjadi andalan untuk terapi pengobatan HIV/AIDS di dunia. Terapi ARV dilakukan untuk menurunkan jumlah virus di dalam tubuh. Tujuan dilakukannya penelitian ini untuk melihat seberapa efektif terapi ARV dalam mengubah jumlah CD4 dalam jangka waktu tertentu. Penelitian ini merupakan penelitian unobtrusive dengan menggunakan metode meta analisis. Penelitian unobtrusive merupakan penelitian yang tidak mengganggu subjek penelitian. Penelitian menggunakan 5 artikel yang berdesain penelitian observasional dengan kriteria yang telah ditentukan. Analisis data yang telah dilakukan menggunakan software CMA versi trial 3.0 dengan tingkat kepercayaan α = 5%. Berdasarkan hasil analisis yang telah dilakukan bahwa nilai mean difference Pada random effect model sebesar 0.499 dengan nilai lower level 0.27 dan nilai upper level 0.728. Nilai p-value untuk random effect size sebesar 0,000 < α (5%) yang artinya bahwa pemberian terapi ARV memberi perubahan jumlah pada jumlah cd4 dalam tubuh. Kesimpulan pada penelitian ini dilihat dari summary effect dari penelitian dengan variabel hipertensi menggunakan random effect model memperoleh nilai beda rata-rata 0.499 , artinya orang yang mendapat terapi ARV mengalami perubahan nilai CD4 rata-rata 0.499 dari pada yang tidak menjalani terapi ARV dengan nilai lower level 0.27 dan nilai upper level 0.728. Nilai p-value untuk random effect model sebesar 0,000 < α (5%) yang artinya bahwa terapi ARV memberi perubahan nilai CD4 dalam tubuh penderita HIV/AIDS.

show abstract

Section: Metodeunclassified

Meta Analisis Beda Rata-Rata Pada Pengobatan HIV/AIDS Di Indonesia

Saniputra

2022

preventif

View full text Add to dashboard Cite

show abstract

“…Another study reported high levels of viral suppression during antiretroviral therapy associated with CD4 cell counts above 500 cells/µL [24]. In addition, the CD4 count of people living with HIV began to increase significantly at 18 months of LTE therapy [25]. CD4 T lymphocytes play an important role in the activation, modulation, coordination, and regulation of adaptive and innate immune responses [26].…”

Section: Introductionmentioning

confidence: 99%

Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

Adiningsih¹,

Widiyanti²,

Rokhmad³

2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

Tenofovir lamivudine efavirenz (TLE) as a single-tablet regimen is preferred to the long use of combination antiretroviral therapy. TLE is safer than another antiretroviral drug regimen for first-line of Human immunodeficiency virus (HIV) treatment. However, there is little information about the side effects of TLE during first-time therapy among people living with HIV in Jayapura. This study aimed to assess the TLE side effect and its efficacy among people living with HIV in Jayapura, Papua. This was a cross-sectional study involving 77 people living with HIV who took a single-tablet regimen of TLE for one to two years of antiretroviral therapy, comply the inclusion criteria, and provided consent to participate. Data collection was conducted through CD4 + tests, medical records, and interviews at Jayapura City Hospital. Descriptive statistics were used to determine the proportion of relevant variables. The results described that most groups of people living with HIV were adult group (93.5%), female (61.0%), Papuan (64.9%), had WHO clinical stage III-IV (67.5%), had CD4 + counts < 350 cell/µL in the early therapy (79.2%) and CD4 + counts ≥ 350 cell/µL at the time of the study (57.1%), and experienced TLE side effect (71.4%). The most symptoms of TLE side effects among people living with HIV were headache (61.8%), nausea (34.5%), and nightmare (29.1%). As many as 70.9% of people living with HIV experienced these symptoms for less than 2 weeks. TLE was still effective, indicated by an increase of CD4 + cell count average from 242.6 cell/mm 3 at the early therapy to 436.6 cell/mm 3 during this study, with good adherence to drug therapy (>95% adherence) by 53.2% of people living with HIV. The side effects of TLE can still be tolerated by most people living with HIV so the therapy can be continued without altering the regimen.

show abstract